Last $20.22 USD
Change Today +0.35 / 1.76%
Volume 117.1K
ATRC On Other Exchanges
As of 8:10 PM 01/23/15 All times are local (Market data is delayed by at least 15 minutes).

atricure inc (ATRC) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/27/14 - $22.52
52 Week Low
10/8/14 - $13.19
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ATRICURE INC (ATRC)

Related News

No related news articles were found.

atricure inc (ATRC) Related Businessweek News

No Related Businessweek News Found

atricure inc (ATRC) Details

AtriCure, Inc., a medical device company, provides atrial fibrillation solutions worldwide. It provides isolator bipolar radio-frequency (RF) ablation clamps that are used for ablation during open-heart procedures; and ablation and sensing unit, a compact power generator that provides the RF energy for its clamps, multifunctional pens, and coolrail linear ablation devices. The company also offers AtriCure Switch Box, a compact switch box, which offers the technology needed for the dual pulsing electrodes in isolator synergy clamps; isolator multifunctional pens that enable surgeons to evaluate cardiac arrhythmias, as well as to perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and coolrail linear ablation device, a disposable linear RF ablation device that allows physicians to create an expanded cardiac ablation lesion set during minimally invasive procedures. In addition, it provides RF ablation devices, such as COBRA Fusion Surgical Ablation System; COBRA Revolution Bipolar Clamp; COBRA Electrosurgical Unit; COBRA Monopolar Surgical Devices; and COBRA AFfirm Bipolar Pacing Probe. Further, the company offers cryoablation system, which is used for afib ablation treatment during certain open-heart procedures; and AtriClip System that is designed to exclude the left atrial appendage by implanting the device during concomitant open surgical procedures. Additionally, it sells technologies, including Lumitip dissector to separate tissues to provide access to anatomical structures that are targeted for ablation; the MicroPace ORLab system, a stimulating, mapping, and recording system; and Estech valve surgical devices that provide solutions with exposure and instrumentation for valve procedures using minimally invasive access. The company sells its products to hospitals and medical centers through independent distributors and direct sales personnel. AtriCure, Inc. is headquartered in West Chester, Ohio.

320 Employees
Last Reported Date: 03/11/14

atricure inc (ATRC) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $500.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $212.5K
Chief Operating Officer
Total Annual Compensation: $300.0K
Senior Vice President of Operations & Quality...
Total Annual Compensation: $278.1K
Vice President and General Manager of Interna...
Total Annual Compensation: $378.8K
Compensation as of Fiscal Year 2013.

atricure inc (ATRC) Key Developments

AtriCure, Inc. Announces Management Changes

AtriCure, Inc. announced that Douglas Seith will assume the role of Chief Operating Officer. Mr. Seith will now be responsible for all global commercial organizations as well as education and clinical science programs. The company also announced that Andy Wade has been promoted to Senior Vice President and Chief Financial Officer. Mr. Seith has over 25 years of cardiology and general surgery sales and sales leadership experience and has served as AtriCure's Senior Vice President, Sales and Marketing since January 2013. Since joining AtriCure in 2004, Mr. Seith has held a variety of progressive sales and sales leadership positions. Prior to joining AtriCure, Mr. Seith held sales leadership or sales positions with A-Med/EmoblX, Inc., where he was the Vice President of Sales, Heartport, Inc., Scimed Life Systems (a division of Boston Scientific, Inc.) and Automated Instruments (a division of United States Surgical Corporation). Andy has served as Vice President and Chief Financial Officer since 2013.

AtriCure, Inc. Announces Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2014 and Provides Earnings Guidance for the Full Year of 2015

AtriCure, Inc. announced revenue guidance for the fourth quarter and full year ended December 31, 2014 and provides earnings guidance for the full year of 2015. For fourth quarter 2014, revenue is expected to be approximately $29.5 million, reflecting growth of approximately 34.6% over the fourth quarter of 2013. Preliminary revenue for full year 2014 is expected to be $107.5 million, reflecting year over year growth of 31.3% over full year 2013. The management projects, that 2015 revenue will be in the range of $122.5 million to $124.5 million, which represents an increase of 14% to 16% over 2014. Adjusted EBITDA, a non-GAAP measure, is projected to be a loss in the range of $7 to $9 million for 2015 as continue to make strategic investments to drive long-term growth plan.

AtriCure, Inc. Receives U.S. Food and Drug Administration Approval for Pivotal Study to Enroll Non-Paroxysmal Afib Patients

AtriCure, Inc. announced it has received approval for an Investigational Device Exemption from the U.S. Food and Drug Administration (FDA) to begin enrollment in the Dual Epicardial and Endocardial Procedure (DEEP) clinical trial. The DEEP trial is a prospective, multicenter, single arm, pivotal study to evaluate patients with persistent or long-standing persistent atrial fibrillation. This is the first pivotal study of its kind in the United States. The study is designed to evaluate the safety and efficacy of the DEEP approach in treating non-paroxysmal (also called persistent, long-standing persistent and permanent) atrial fibrillation. The DEEP approach utilizes the specialized skills of both the cardiac surgeon and electrophysiologist (EP) to treat more severe cases of Afib, such as non-paroxysmal, which historically have been the most difficult to treat. In the DEEP study, the cardiac surgeon and EP work as a team to perform a minimally invasive epicardial (outside the heart) ablation and endocardial (inside the heart) catheter-based ablation. The primary effectiveness endpoint is freedom from Afib and freedom of Class I or III antiarrhythmic drug therapy. AtriCure has FDA approval to enroll 220 subjects at up to 25 sites in the U. S. and internationally. The principal investigators for DEEP are Dr. Kenneth Ellenbogen, Chairman of the Division of Cardiology at Virginia Commonwealth University (VCU) Pauley Heart Center; Dr. Paul Wang, Director, Stanford Arrhythmia Service, Professor of Medicine and Bioengineering, by courtesy, Stanford University School of Medicine; Dr. Vigneshwar Kasirajan, Chairman, Department of Surgery and Division of Cardiothoracic Surgery and Professor, Department of Surgery at VCU Pauley Heart Center; and Dr. Ali Khoynezhad, Professor of Cardiovascular Surgery at Cedars-Sinai Heart Institute.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ATRC:US $20.22 USD +0.35

ATRC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cerus Corp $5.29 USD -0.02
CryoLife Inc $11.74 USD -0.05
STAAR Surgical Co $7.17 USD 0.00
SurModics Inc $22.06 USD -0.21
Vascular Solutions Inc $28.86 USD -0.06
View Industry Companies

Industry Analysis


Industry Average

Valuation ATRC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.5x
Price/Book 4.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ATRICURE INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at